Hygieia announces CE Mark approval in the European Union for its D-Nav Diabetes Insulin Guidance System for treating patients with poor glycemic control.

Diabetes healthcare company Hygieia's d-Nav Diabetes Insulin Guidance System (DIGS) won CE Mark approval in the European Union for treatment of patients with poor glycemic control.

DIGS automatically updates insulin dosage as needed, providing users with the updates at-time rather than requiring a clinical visit. A pair of U.K. diabetes centers plan to start using d-Nav this fall, and an Irish hospital will begin a 6-month service evaluation of the technology, according to a press release.